Quantifying the association between neutralising antibodies and protection from RSV disease in infants and adults: A systematic review and meta-analysis
Authors:
- Alexandra B HoganAHAlexandra B Hogan
- Ainslie MitchellAMAinslie Mitchell
- Eva StadlerESEva Stadler
- Yuna ChungYCYuna Chung
- Arnold ReynaldiARArnold Reynaldi
- Karen M EliasKEKaren M Elias
- Steffen DockenSDSteffen Docken
- David S KhouryDKDavid S Khoury
- Timothy SchlubTSTimothy Schlub
- Miles P DavenportMDMiles P Davenport
- Deborah CromerDCDeborah Cromer
Preprint
Abstract
A number of vaccines and long-acting monoclonal antibodies have been shown to be effective in the prevention of respiratory syncytial virus (RSV) disease. However, an immune correlate of protection for RSV has not yet been identified. We conducted a systematic review to identify published reports of immunogenicity and/or efficacy in vaccines and long-acting monoclonal antibodies against RSV and performed a meta-analysis on extracted data to identify any relationship between antibody increase and protection against RSV disease. We identified 130 relevant reports which we classified into an open access evidence map of RSV immunisation products. We found a strong correlation between the immunisation induced rise in neutralising antibody titres and efficacy (ρ>0.7 for all comparisons, Spearman). For infants, we estimated that each 10-fold increase in neutralising antibody titre rise provides an additional 31% [95% CI 10%, 47%], 47% [95% CI 36%, 56%] and 57% [95% CI 45%, 66%] reduction in the relative risk of symptomatic, moderate and severe disease respectively. For older adults, a 10-fold rise in antibody levels was associated with a 34% [95% CI -2%, 57%], 50% [95% CI 22%, 67%] and 63% [95% CI 36%, 79%] reduction in the relative risk of RSV disease with 1, 2 and 3 symptoms respectively. These results align extremely well with findings from natural history studies and individual-based analysis of correlates of protection studies. This work paves the way for use of neutralising antibodies as a correlate of protection to guide the development, approval, and deployment of RSV vaccines and monoclonal antibodies.Keywords
This publication has 117 references indexed in Scilit:
- Clesrovimab: First ApprovalDrugs, 2025
- Lot-to-lot immunogenicity consistency of the respiratory syncytial virus prefusion F protein vaccine in older adultsVaccine: X, 2024
- Safety and immunogenicity of a respiratory syncytial virus prefusion F protein (RSVPreF3) candidate vaccine in older Japanese adults: A phase I, randomized, observer-blind clinical trialRespiratory Investigation, 2023
- Correlates of Protection Against Respiratory Syncytial Virus Infection in InfancyClinical Reviews in Allergy & Immunology, 2022
- Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein induces genetically and antigenically diverse antibody responsesImmunity, 2021
- A Phase 1 Randomized, Double‐Blind, Placebo‐Controlled Trial to Assess the Safety, Tolerability, and Pharmacokinetics of a Respiratory Syncytial Virus Neutralizing Monoclonal Antibody MK‐1654 in Healthy AdultsClinical Pharmacology in Drug Development, 2020
- Safety and immunogenicity evaluation of recombinant BCG vaccine against respiratory syncytial virus in a randomized, double-blind, placebo-controlled phase I clinical trialeClinicalMedicine, 2020
- Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adultsJournal of Infection, 2019
- Outcomes of Respiratory Syncytial Virus Immunoprophylaxis in Infants Using an Abbreviated Dosing Regimen of PalivizumabJAMA Pediatrics, 2016
- Respiratory syncytial virus neutralizing antibodies in cord blood, respiratory syncytial virus hospitalization, and recurrent wheezeJournal of Allergy and Clinical Immunology, 2009